Clinical Trials Browser

Phase 1/2 × aumolertinib × 1 year × Clear all

NCT06947811 2025-06-04

APEAK

Phase 1/2 Recruiting

EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor